Clinical trials
Hematologic Diseases clinical trials
Below are recruiting hematologic diseases clinical trials, each written for real people, not researchers. We’re tracking 247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06158269RecruitingPhase 2
DVRd treatment for newly diagnosed double-hit myeloma
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
TianjinAges 18–70 - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06219239Recruiting
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06238908RecruitingEarly Phase 1
Gene therapy NGGT003 for severe hemophilia A
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06254560RecruitingPhase 2
Rituximab for severe aplastic anemia with platelet transfusion problems
This study tests if the drug rituximab can help people with severe aplastic anemia whose bodies have stopped responding to platelet transfusions. It aims to see if rituximab can improve the body's ability to accept platelets again.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06386302Recruiting
Chidamide, venetoclax, and azacitidine for new AML
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06387121RecruitingPhase 2
Low-dose chemo plus immune drugs for new B-ALL
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06415708RecruitingPhase 2
Obinutuzumab with bendamustine for B-cell lymphoma
This trial tests a combination of two drugs—obinutuzumab and bendamustine—for people with certain B-cell lymphomas that haven't been treated before. The goal is to see how well this combination works and how safe it is.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06427330RecruitingPhase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
TianjinAges 18 years+ - NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
TianjinAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06513234RecruitingPhase 2
Orelabrutinib and Obinutuzumab for untreated marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
TianjinAges 18 years+ - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06530576RecruitingPhase 2
Thalidomide for symptomatic large granular lymphocytic leukemia
This trial tests the drug thalidomide for people with symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. It aims to see if thalidomide can help control the disease and improve symptoms like low blood counts or an enlarged spleen.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06594640RecruitingPhase 1/Phase 2
R-CMOP for newly diagnosed diffuse large B-cell lymphoma
This trial tests a new combination of drugs (R-CMOP) for people who have just been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) and have not yet received any treatment for it. The goal is to see if this treatment works well and is safe.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06608342RecruitingPhase 2
Stem cell transplant plus CAR-T for high-risk leukemia
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06613880RecruitingPhase 2
Romiplostim with standard therapy for severe aplastic anemia
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
Tianjin, Tianjin MunicipalityAges 12 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06635681RecruitingPhase 2
Venetoclax plus intensive chemo for AML subtypes
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06695741RecruitingPhase 2
Lower dose cyclophosphamide with standard therapy for severe aplastic anemia
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Tianjin, Tianjin MunicipalityAges 12 years+
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic diseases?
- Yes. Clin2 currently lists 247 recruiting hematologic diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.